Health-care shares were flat to higher in
Roka Bioscience (
), a molecular-diagnostics company, said its Q2 loss shrank as
revenue more than doubled. Roka reported its Q2 net loss narrowed
to $7.4 million, or a loss of $11.28 per share, from $7.9 million,
or a loss of $15.96 per share, in the same period last year. ROKA
shares were steady at $10.49 pre-market.
), which develops consumable products for biological drugs, Q2
results above analysts' expectations and raised its revenue
guidance for the year. RGEN was up more than 4% pre-market.
Repligen's net income declined to $2.8 million, or $0.09 per share,
from $4.5 million, or $0.14 per share, a year earlier. Two analysts
surveyed by Capital IQ had predicted a profit of $0.06 per share,
), a biomedical company, reported narrower-than-estimated loss in
Q2 as revenue more than doubled. Its Q2 net loss expanded to $6
million, or $0.39 loss per diluted share, in the April-to-June
period, from $2.1 million, or $0.33 loss per diluted share, a year
Molina Healthcare (
) announced late Friday its Molina Healthcare of Florida subsidiary
signed an agreement with First Coast Advantage to acquire certain
assets tied to First Coast Advantages' Medicaid business. Financial
terms of the deal weren't disclosed. MOH trades in a 52-week range
of $31.10 to $47.22, with shares steady at $40.63 pre-market.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.